Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6UEI3
|
|||
| Drug Name |
LX1001
|
|||
| Synonyms |
AAVrh.10hAPOE2
Click to Show/Hide
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1/2 | [1] | |
| Company |
Lexeo Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Apolipoprotein E (APOE) | Target Info | . | [2] |
| KEGG Pathway | Alzheimer's disease | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| FSH Signaling Pathway | ||||
| Wnt Signaling Pathway | ||||
| Reactome | Chylomicron-mediated lipid transport | |||
| HDL-mediated lipid transport | ||||
| Scavenging by Class A Receptors | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Statin Pathway | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Binding and Uptake of Ligands by Scavenger Receptors | ||||
| Visual phototransduction | ||||
| Lipid digestion, mobilization, and transport | ||||
| Alzheimers Disease | ||||
| Vitamin B12 Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03634007) A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Lexeo Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.